They are primarily prescribed for the management of type 2 diabetes mellitus (semaglutide [Ozempic], liraglutide [Victoza], dulaglutide [Trulicity], exenatide [Byetta, Bydureon BCise]) and, with separate formulations, for weight management in adults with obesity or overweight with weight-related comorbidities (semaglutide [Wegovy], liraglutide [Saxenda])
Appetite and Satiety Regulation: Directly modulates central nervous system hunger pathways, significantly delaying gastric emptying to keep you feeling full longer and curb caloric cravings
Testing is available for $99 after your first month of treatment
However, their GH release characteristics differ
--- BPC-157 and the Changing Regulatory Landscape The timing of this human data matters
doi: 10.1016/j.hoc.2009.11.011 3 ParkJRBagatellRLondonWBMarisJMCohnSLMattayKMet al